EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The platelet‐to‐lymphocyte ratio is a complementary prognostic factor to tumor markers in predicting early recurrence of hepatocellular carcinoma after hepatectomy

Kiyotaka Hosoda, Kentaro Umemura, Akira Shimizu, Koji Kubota, Tsuyoshi Notake, Noriyuki Kitagawa, Hiroki Sakai, Hikaru Hayashi, Koya Yasukawa, Yuji Soejima

Journal of Surgical Oncology · 2024

DOI: 10.1002/jso.27564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Kiyotaka Hosoda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Shinshu University School o…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The usefulness of inflammation‐based prognostic scores for early recurrence (ER) after hepatectomy for hepatocellular carcinoma has rarely been reported. This study aimed to evaluate the potential of inflammation‐based prognostic scores as predictors of ER and their relationship with tumor markers.

Methods

We enrolled 338 patients who underwent hepatectomy for hepatocellular carcinoma between January 2007 and December 2021. Clinicopathological factors were compared between patients who developed ER (ER group) and those who did not develop ER (non‐ER group). The association between inflammation‐based prognostic scores and ER status was evaluated. These scores were compared with those of well‐established tumor markers.

Results

The platelet‐to‐lymphocyte ratio (PLR) correlated with ER of hepatocellular carcinoma, with an area under the curve (AUC) value of 0.70, sensitivity of 68.1%, and specificity of 67.7%. In patients with low tumor marker levels, the PLR showed a strong correlation with ER of hepatocellular carcinoma, with an AUC value of 0.851, sensitivity of 100%, and specificity of 76.2%. Multivariate analysis revealed that the PLR was an independent prognostic factor for ER.

Conclusions

The PLR is useful and complementary to tumor markers for predicting ER after hepatectomy for hepatocellular carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansHepatectomyPrognosisBiomarkers, TumorLymphocytesInflammationRetrospective Studies

Stichwörter der Autor:innen

early recurrencehepatocellular carcinomainflammation-based prognostic scoresplatelet-to-lymphocyte ratiotumor marker

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Surgery, Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Shinshu University School of Medicine, Matsumoto, Japan.

Zitieren

APA

Hosoda, K., Umemura, K., Shimizu, A., Kubota, K., Notake, T., Kitagawa, N., Sakai, H., Hayashi, H., Yasukawa, K., & Soejima, Y. (2024). The platelet‐to‐lymphocyte ratio is a complementary prognostic factor to tumor markers in predicting early recurrence of hepatocellular carcinoma after hepatectomy. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27564

Vancouver

Hosoda K, Umemura K, Shimizu A, Kubota K, Notake T, Kitagawa N, et al. The platelet‐to‐lymphocyte ratio is a complementary prognostic factor to tumor markers in predicting early recurrence of hepatocellular carcinoma after hepatectomy. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27564

BibTeX
@article{Hosoda2024,
  author = {Hosoda, Kiyotaka and Umemura, Kentaro and Shimizu, Akira and Kubota, Koji and Notake, Tsuyoshi and Kitagawa, Noriyuki and Sakai, Hiroki and Hayashi, Hikaru and Yasukawa, Koya and Soejima, Yuji},
  title = {The platelet‐to‐lymphocyte ratio is a complementary prognostic factor to tumor markers in predicting early recurrence of hepatocellular carcinoma after hepatectomy},
  journal = {Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1002/jso.27564}
}
Kostenlos starten →